| INTRODUCTION
Childhood obesity has emerged as a global public health concern over the past three decades, with prevalence having doubled in more than 70 countries. 1 In the United States, the prevalence of obesity nearly tripled in school-age children (6-11 y) from 6.5% to 18.0% between 1976-1980 and 2009-2010 . 2 Childhood obesity is associated with a number of health complications including type 2 diabetes mellitus, hypertension, polycystic ovary syndrome, sleep apnoea, asthma, orthopaedic problems, and psychosocial problems. [3] [4] [5] Furthermore, childhood overweight is associated with risk factors for cardiovascular disease. 6, 7 Childhood overweight and obesity are independent risk factors for developing obesity in adulthood, 8 and the relative risk of adult obesity increases with age and body mass index (BMI). 9 Taken together, these findings underscore the need to implement safe and efficacious interventions to treat and prevent obesity in children.
Interventions for treating obesity in children have shown limited effectiveness, with the foundation of current treatment strategies focusing on family-based behavioural programmes. 3 If lifestyle modifications to diet and physical activity levels fail, an escalation in medical therapy may be required, including pharmacological treatment. 3 Orlistat and phentermine are the only medications approved in the United States to treat obesity in adolescents (age ≥ 12 and ≥16 y, respectively). Studies of medications to treat obesity in children had small sample sizes or revealed only modest effects on weight loss. [10] [11] [12] Currently, there are no pharmacotherapies approved for weight management in young children below the age of 12 in either the United States or European Union (EU). As such, there exists an unmet medical need in this population for the treatment of obesity.
Liraglutide is an analogue of the gut incretin hormone GLP-1. 13 In response to food intake, GLP-1 is secreted by intestinal L cells and lowers blood glucose by inhibiting glucagon secretion and promoting insulin secretion in a glucose-dependent manner. 13, 14 GLP-1 is also a physiological regulator of appetite. Liraglutide belongs to the class of GLP-1 receptor agonists 13 that stimulates weight loss via reductions in appetite and energy intake. 15 Liraglutide 3.0 mg, as an adjunct to a reduced-calorie diet and increased physical activity, is approved for chronic weight management in adults based on the phase 3a Satiety
and Clinical Adiposity-Liraglutide Evidence (SCALE) clinical development programme. [16] [17] [18] [19] [20] In a previous trial of adolescents with obesity, treatment with liraglutide 3.0 mg revealed no safety or tolerability concerns, and the pharmacokinetic (PK) properties were consistent with previous observations in adults with obesity. 21, 22 The aim of the present trial was to investigate safety, tolerability, PK, and PD during short-term treatment with once-daily liraglutide doses up to 3.0 mg in children with obesity aged 7 to 11 years and 
| Randomization and treatment
Each trial site was supplied with trial products via an interactive voice/web responsive service. Following screening, participants were randomized 2:1 to once-daily subcutaneous injections of liraglutide or placebo, respectively, in accordance with a dispensing unit number allocated by the sponsor. The sponsor, participants, and investigators remained blinded to treatment allocation. Participants and their parents or legally acceptable representatives were instructed in administering injections, and participants performed a self-injection with a prefilled placebo pen injector (FlexPen; Novo Nordisk, Denmark) at the screening visit to ensure they were capable and willing to selfinject. Liraglutide or equal volume of placebo was administered using a prefilled syringe at 9 AM ± 2 hours starting at 0.3 mg once daily. ) in the presence of hypoglycaemia symptoms during the previous week, or if the dose was not tolerated with respect to adverse events (AEs), as judged by the investigator.
Participants attended a final follow-up visit approximately 10 to 17 days after the last dose.
Treatment compliance was assessed by measuring liraglutide concentrations once at each dose step as part of the PK assessment (C trough ), as mentioned below. Additionally, at each dosing visit, the investigator reminded the participants to follow protocol procedures, and the participants returned all used, partly used, and unused trial products. In case of discrepancies, the investigator was to question the child and parent(s)/legally acceptable representative. Moreover, the diaries, in which the time of dosing was to be noted, were checked at each visit.
| Outcomes
The was investigated in full and reduced models; the full model tested effects of all covariates simultaneously, whereas the reduced model removed the least significant covariates sequentially. This model was fitted to data from the current trial and previous trials in adolescents 21 and adults, 22 and the estimated PK parameters were compared.
Changes in BMI Z score and body weight were analysed using a linear model with treatment as a fixed factor with two levels (liraglutide and placebo) and baseline values as covariate. Assessments of FPG, serum insulin, and serum HbA1c were summarized using descriptive statistics.
| RESULTS
A total of 33 participants were screened for eligibility between 14
March 2016 and 13 April 2017, of which nine were screen failures (one was an eligible participant who could not self-inject and was not randomized) ( Figure S2 ). The remaining 24 participants were randomized and exposed to treatment: 16 to liraglutide and eight to placebo. A total of four participants were withdrawn after randomization Baseline characteristics are shown in Table 1 . The mean age was 9.9 years (age range 7-11 y). A total of three participants (one liraglutide-treated and two placebo-treated participants) were reported to have premature adrenarche at the time of screening. The frequency of male participants was higher in the placebo group than the liraglutide treatment group. The mean height and weight of the liraglutide treatment group were less than the placebo group. Baseline BMI Z score and glycaemic parameters (serum HbA1c and FPG) were similar between treatment groups.
| Adverse events
A total of 9/16 (56.3%) participants treated with liraglutide reported 37 AEs and 5/8 (62.5%) participants treated with placebo reported 12 AEs; the AEs are presented by system organ class in Table 2 and additionally by preferred term in Table S3 . All AEs were mild in severity with the exception of three moderate severity AEs (two events (Tables 2 and 3 ). More participants in the liraglutide treatment group (37.5%), compared with placebo group participants (12.5%), reported GI AEs (Table 2) ; however, there was no clear association between the treatment dose, timing, duration, or severity of specific GI AEs (nausea, vomiting, and upper abdominal pain) ( Figure 1 ). Two participants treated with liraglutide (12.5%), compared with no participants in the placebo group, reported three AEs (two events of injection site induration and one event of injection site reaction) that were judged by investigators to be possibly or probably related to treatment (Table 3) . Apart from two events of headache, which were reported by two participants (12.5%) in the liraglutide group and none in the placebo group, other potentially related AEs were single events in either treatment group. All AEs had outcomes of recovered or recovering at the end of the trial. The AEs with outcomes of recovering concerned one participant in the liraglutide treatment group (rash) and two participants in the placebo group (headache and increased alanine aminotransferase).
| Hypoglycaemic episodes
A total of six hypoglycaemic episodes were reported during the trial, of which five were reported in four participants in the liraglutide treatment group (Table 2 ). All episodes were asymptomatic, and four episodes, all in participants treated with liraglutide, occurred following an overnight fast. Glucose measurements reported as hypoglycaemia in participant diaries ranged from 3.4 to 3.9 mmol L −1
(62-70 mg dL −1 ). No treatment was required for these participants.
| Clinical laboratory evaluations, ECG, physical examination, and vital signs
No clinically relevant safety findings were identified in relation to physical exam, vital signs, ECG, haematology, biochemistry, hormones, ); probable symptomatic, symptoms without PG determination; relative, typical symptoms but PG concentration > 70 mg dL −1 (3.9 mmol L −1 ). 27 A total of six hypoglycaemic episodes were reported; there were no severe, documented symptomatic, probable symptomatic, or relative hypoglycaemic episodes.
lipids, or calcitonin. Increases in mean serum lipase and amylase were observed in liraglutide-treated participants ( Figures S3 and S4) ; nevertheless, the changes were not considered to be clinically relevant (all elevated levels were below three times the upper limit of the normal range). No participants developed antiliraglutide antibodies.
| Pharmacokinetics
Liraglutide C trough concentrations were consistent with dose propor- The population PK analysis allowed for comparison of liraglutide exposure between children participating in the current trial and previous trials including adolescents 21 and adults. 22 The mean estimate of CL/F in children was lower than that in both adolescents and adults (Table 4) . Correspondingly, the model-derived mean estimate of AUC 0-24h at steady state following last dose was higher in children compared with adolescents and adults (Table 4 ). Estimated C avg was higher in children compared with adults ( Figure 2A and Table 4 ). These differences can be explained by the fact that body weight was the only covariate of importance for liraglutide exposure. When adjusted for body weight, the exposure was similar for children, adolescents, and adults ( Figure 2B ).
| Pharmacodynamic evaluations
From baseline to end of treatment (7-8 wk after first dose), a statistically significant reduction in BMI Z score was observed in liraglutide- (Table S4 ). There were no differences in levels of serum insulin and HbA1c observed between treatment groups (Table S4 ).
| DISCUSSION
This trial was performed as part of a paediatric clinical development programme for liraglutide in weight management in agreement with regulatory agencies in the United States and EU. This trial follows the earlier trial in adolescents, 21 and, hence, the development plan uses a staggered approach. The safety profile observed in children aged 7 to 11 years was similar to that in liraglutide trials conducted in adults or adolescents with obesity and without diabetes, 16, 17, [19] [20] [21] with no new safety concerns identified.
The frequencies of AEs were similar between liraglutide and placebo treatment groups. More AEs associated with GI disorders, most notably nausea and vomiting, occurred in participants treated with liraglutide compared with placebo, which is consistent with findings 21 and adults. 22 from previous trials in adolescents and adults. 15, 16, 18, 21 There was no clear relationship between treatment dose, timing, duration, or severity of specific GI AEs in children, which is consistent with previous findings in adolescents with obesity. 21 Nausea and vomiting occurred primarily within the first 4 to 8 weeks following initiation of liraglutide treatment in previous weight management trials in adults. 16, 18 Additionally, more related AEs of injection site induration and injection site reactions (three events in total) were reported in liraglutide-treated participants as compared with no events in placebo, similar to previous findings in adolescents with obesity, 21 although the overall frequency of such events was low.
More hypoglycaemic episodes were reported in the liraglutide group compared with the placebo group in the present trial. All events were asymptomatic and only detected during study-related FPG self-measurements. In a previous trial with adolescents, more hypoglycaemic events were observed in participants treated with liraglutide, and nearly half of the events occurred following an overnight fast of 10 hours or more. 21 These findings indicate that extended fasting in conjunction with liraglutide treatment may have contributed to episodes of hypoglycaemia, as suggested previously. 21 In general, all other safety parameters indicated no clinically relevant findings. Treatment with liraglutide resulted in increased lipase and amylase levels (all below three times the upper limit of the normal range), consistent with previous observations in adolescents 21 and adults with obesity. 15, 16, 18 In SCALE trials in adult participants with overweight and obesity, the elevations of amylase and lipase occurring in those treated with liraglutide did not predict acute pancreatitis, and levels returned to baseline levels following discontinuation of therapy. 32 Furthermore, the clinical relevance and mechanisms underlying these increases remain unclear. 32 The potential effects of liraglutide on blood pressure and pulse could not be determined in this shortterm trial.
The PK analyses of liraglutide revealed that liraglutide C trough values were consistent with dose proportionality. The joint population PK analysis for liraglutide in children, adolescents, and adults confirmed that body weight was a relevant covariate for exposure, in agreement with previous observations; thus, a lower body weight is associated with a higher liraglutide exposure. 22, 33, 34 Unlike the previous trial in adults, 22 sex was not a relevant covariate on exposure in children aged 7 to 11 years; however, this may be due to the low number of female children in the current study. A thorough investigation of sample handling, bioanalysis, subject diaries, and drug accountability records did not provide an explanation for the unexpectedly low concentrations of liraglutide in four participants. Hence, the cause of these low concentrations was not determined. Treatments administered subcutaneously require the ability and willingness to self-inject;
thus, support and guidance from parents and caregivers are paramount in order to ensure optimal adherence to therapy. The limitations in the current study include the variability between the treatment groups. The placebo group contained more males, and participants on average tended to be taller and heavier.
Fewer female children participated in the study, likely due to the pubertal exclusion criteria. The short duration of the current trial poses limitations in that long-term safety could not be assessed in this trial of approximately 7 weeks' duration. Similarly, although exploratory PK analyses indicated a relationship between exposure and response, the full exposure-response is not expected from this shortterm trial.
In summary, treatment with liraglutide in this paediatric population aged 7 to 11 years showed no unexpected safety or tolerability concerns in the present trial, with no new safety issues as compared with previous trials conducted in adolescents or adults with obesity.
Participants treated with liraglutide for up to 8 weeks achieved a statistically significant reduction in BMI Z score, nonsignificant decrease in body weight, and minor reduction in FPG. However, because of the short-term treatment in this trial, the pharmacodynamic results should be interpreted with caution. Liraglutide exposure at steady state was consistent with dose proportionality. Furthermore, the joint population PK analysis revealed that body weight was the only relevant covariate to predict liraglutide exposure; no differences were detected between age groups or sex. These findings support further (A) (B) FIGURE 2 Dose-normalized average concentrations in children, adolescents, and adults (A) before and (B) after adjustment for differences in body weight. Individual data points are represented by shaded rectangles. Squares indicate geometric mean model-based estimates of the average concentration in steady state with 95% CI for each trial assuming full compliance to liraglutide 3.0 mg treatment. Data in (B) are adjusted on the basis of individual body weights. Mean body weights are shown. Data are from the current trial in children and previous clinical pharmacology trials in adolescents 21 and adults. 22 BW, body weight; C avg , estimated average plasma liraglutide concentration in a dosing interval at steady state; CI, confidence interval; N, number of participants analysed long-term investigations of safety and efficacy in young children with obesity and will guide dose setting in planned phase 3 trials in this age group.
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